What is Tempest Therapeutics, Inc.'s earnings per share (EPS)?

Tempest Therapeutics, Inc. (TPST) reported diluted earnings per share of -$6.33 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Tempest Therapeutics, Inc. (TPST) Financials

TPST

FY2025 annual

Net Income -$26.3M +37.2% YoY

EPS (Diluted) -$6.33 YoY not available

Free Cash Flow -$26.8M +19.8% YoY

Operating Cash Flow -$26.8M +18.8% YoY

Market Cap $12.8M as of Oct 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TPST SEC filings page.

This page shows Tempest Therapeutics, Inc. (TPST) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TPST FY2025 2026-10-03

Tempest remains a development-stage cash consumer: FY2025 losses narrowed mainly through lower R&D, while its balance sheet became thinner.

The FY2025 net loss of $26.3M nearly matched operating cash outflow of $26.8M, with no capital spending; reported losses therefore translated almost dollar-for-dollar into cash use rather than reflecting mainly noncash charges.

The operating loss narrowed from $42.0M in FY2024 to $26.6M in FY2025. R&D fell from $28.5M to $12.6M while SG&A remained roughly flat, so the improvement appears driven by development-spending cuts rather than broader operating leverage.

Assets fell from $41.5M in FY2024 to $16.9M in FY2025, while equity reached just $6.7M; the shrinking base leaves less balance-sheet capacity behind ongoing development. The current ratio remained 2.5x, but debt-to-equity rose from 0.0x to 1.5x, showing that short-term liquidity did not coincide with a strengthening capital base. Reported liquidity equaled 3.4 months of FY2025 operating outflow, while financing cash flow was positive $4.3M, making external financing part of the reported funding pattern.

Financial Health Signals

Financial health score not available

Tempest Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Tempest Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Tempest Therapeutics, Inc. reported a net loss of $26.3M while operations used $26.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Tempest Therapeutics, Inc. reported an operating loss of $26.6M against $207K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$5.2M

YoY+34.3%

QoQ+81.2%

Tempest Therapeutics, Inc.'s EBITDA was -$5.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 34.3% from the same quarter a year earlier. Against the prior quarter it is up 81.2%.

Net Income

-$5.2M

YoY+33.4%

QoQ+81.1%

Tempest Therapeutics, Inc. reported -$5.2M in net income in Q2 2026. This represents an increase of 33.4% from the same quarter a year earlier. Against the prior quarter it is up 81.1%.

EPS (Diluted)

-$0.34

QoQ+86.6%

Tempest Therapeutics, Inc. earned -$0.34 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 86.6%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$2.8M

YoY+67.0%

QoQ+63.4%

Tempest Therapeutics, Inc. recorded an outflow of $2.8M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 67.0% from the same quarter a year earlier. Against the prior quarter it is up 63.4%.

Cash & Debt

$779K

YoY-94.5%

QoQ-56.8%

5Y CAGR-59.1%

10Y CAGR-38.2%

Tempest Therapeutics, Inc. held $779K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

16M

QoQ+7.9%

5Y CAGR+19.0%

10Y CAGR-7.7%

Tempest Therapeutics, Inc. had 16M shares outstanding in Q2 2026. Against the prior quarter it is up 7.9%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

R&D Spending

$1.8M

YoY-53.0%

QoQ+1495.6%

Tempest Therapeutics, Inc. invested $1.8M in research and development in Q2 2026. This represents a decrease of 53.0% from the same quarter a year earlier. Against the prior quarter it is up 1495.6%.

Capital Expenditures

Tempest Therapeutics, Inc. reported no capital expenditure in Q2 2026.

Share Buybacks

Not reported for Q2 2026.

TPST Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TPST quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$295K-54.8%	$653K+135.7%	$277K	$0	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$790K-85.4%	$5.4M+140.2%	$2.2M	$0	$0	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$495K+89.6%	-$4.7M-140.8%	-$2.0M	$0	$0	N/A	N/A
R&D Expenses	N/A	$12.6M-55.7%	$28.5M+62.7%	$17.5M-22.3%	$22.5M+31.2%	$17.2M+19.3%	$14.4M-48.3%	$27.8M+93.0%	$14.4M-21.3%	$18.3M-15.3%	$21.6M+17.4%	$18.4M-15.4%	$21.8M+37.9%	$15.8M+149.9%	$6.3M	N/A
SG&A Expenses	N/A	$14.0M+3.1%	$13.6M+16.2%	$11.7M-3.7%	$12.1M+23.4%	$9.8M+100.0%	$4.9M-72.0%	$17.6M+102.0%	$8.7M-68.7%	$27.7M-43.6%	$49.2M-4.6%	$51.6M+97.3%	$26.1M+96.1%	$13.3M+85.0%	$7.2M	N/A
Operating Income	N/A	-$26.6M+36.8%	-$42.0M-44.1%	-$29.2M+15.8%	-$34.6M-28.4%	-$27.0M-39.8%	-$19.3M+57.5%	-$45.4M-68.9%	-$26.9M+68.1%	-$84.3M-4.1%	-$81.0M-12.5%	-$72.0M-50.2%	-$47.9M-64.5%	-$29.1M-115.3%	-$13.5M	N/A
EBITDA	N/A	-$26.3M+36.8%	-$41.6M-44.7%	-$28.8M+15.4%	-$34.0M-27.8%	-$26.6M-40.4%	-$19.0M+58.1%	-$45.3M-68.8%	-$26.8M+67.5%	-$82.7M-5.0%	-$78.8M-11.4%	-$70.7M-48.9%	-$47.5M-64.3%	-$28.9M-115.1%	-$13.4M	N/A
Interest Expense	N/A	$207K-84.3%	$1.3M-9.2%	$1.4M-10.4%	$1.6M+26.2%	$1.3M	$0	N/A	$134K-53.5%	$288K	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	N/A	N/A	$67K-66.7%	$201K+168.0%	$75K	$0	$0	$0	$0
Net Income	N/A	-$26.3M+37.2%	-$41.8M-41.9%	-$29.5M+17.4%	-$35.7M-26.2%	-$28.3M-47.3%	-$19.2M+56.9%	-$44.6M-63.9%	-$27.2M+67.8%	-$84.6M-2.8%	-$82.3M-12.3%	-$73.2M-47.9%	-$49.5M-70.5%	-$29.0M-115.0%	-$13.5M	N/A
EPS (Basic)	N/A	-$6.33+67.5%	-$19.50-920.9%	-$1.91+38.2%	-$3.09+58.6%	-$7.47+81.8%	-$41.03	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$6.33	-$19.50	-$1.91	-$3.09	-$7.47	-$41.03	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	4M	2M	15M	12M	4M	468,161	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$1.8M-53.0%	$114K-98.5%	N/A	$570K-92.5%	$3.9M-33.7%	$7.6M+75.7%	N/A	$7.6M+79.0%
SG&A Expenses	$3.4M-16.2%	$5.4M+63.9%	N/A	$3.0M+1.1%	$4.1M+9.3%	$3.3M-8.9%	N/A	$3.0M+26.3%
Operating Income	-$5.3M+34.1%	-$27.7M-153.5%	N/A	-$3.6M+65.9%	-$8.0M+16.9%	-$10.9M-37.1%	N/A	-$10.6M-60.1%
EBITDA	-$5.2M+34.3%	-$27.7M-154.5%	N/A	-$3.5M+66.2%	-$7.9M+16.2%	-$10.9M-37.8%	N/A	-$10.5M-60.7%
Interest Expense	$0-100.0%	$0-100.0%	N/A	$0-100.0%	$46K-87.6%	$161K-56.3%	N/A	$329K-11.8%
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$5.2M+33.4%	-$27.7M-155.0%	N/A	-$3.5M+66.7%	-$7.9M+17.8%	-$10.9M-37.4%	N/A	-$10.6M-55.6%
EPS (Basic)	-$0.34+83.6%	-$2.53+19.9%	-$0.62-100.0%	-$0.79+85.2%	-$2.07+62.5%	-$3.16+31.6%	-$0.31+8.8%	-$5.32-1008.3%
EPS (Diluted)	-$0.34	-$2.53	-$0.62	-$0.79	-$2.07	-$3.16	-$0.31	-$5.32
Diluted Shares (Avg)	15M	11M	N/A	4M	4M	3M	N/A	2M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

TPST Balance Sheet

TPST quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$16.9M-59.2%	$41.5M-19.6%	$51.6M+12.0%	$46.1M-37.1%	$73.2M+220.3%	$22.9M-69.5%	$75.0M-10.8%	$84.1M+324.4%	$19.8M-83.8%	$122.5M-11.6%	$138.6M+111.4%	$65.6M+37.9%	$47.5M+44.9%	$32.8M+615.7%	$4.6M
Current Assets	$8.3M-73.7%	$31.5M-22.0%	$40.4M+22.5%	$33.0M-52.2%	$69.0M+247.9%	$19.8M-72.1%	$71.1M-14.7%	$83.4M+322.6%	$19.7M-83.0%	$116.4M-10.3%	$129.9M+109.9%	$61.9M+37.3%	$45.1M+41.0%	$32.0M+597.2%	$4.6M
Cash & Equivalents	$7.7M-74.5%	$30.3M-22.8%	$39.2M+25.6%	$31.2M-39.7%	$51.8M+175.4%	$18.8M-69.9%	$62.5M-14.7%	$73.3M+316.9%	$17.6M-60.0%	$43.9M+1.6%	$43.2M+573.9%	$6.4M-64.5%	$18.1M+22.3%	$14.8M+225.4%	$4.5M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$70.5M-15.6%	$83.4M+55.0%	$53.8M+104.2%	$26.3M+58.6%	$16.6M	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$10.3M-54.1%	$22.4M-10.0%	$24.8M-11.2%	$28.0M-24.6%	$37.1M-59.5%	$91.7M-26.9%	$125.3M+1044.4%	$11.0M-92.7%	$150.5M+950.7%	$14.3M+21.8%	$11.8M+14.8%	$10.2M+75.3%	$5.8M+179.2%	$2.1M-69.9%	$7.0M
Current Liabilities	$3.3M-76.7%	$14.2M+51.1%	$9.4M+29.3%	$7.3M-63.7%	$20.0M+521.5%	$3.2M-74.3%	$12.5M+27.5%	$9.8M+140.0%	$4.1M-69.0%	$13.2M+17.5%	$11.2M+10.5%	$10.2M+76.2%	$5.8M+176.8%	$2.1M+209.0%	$675K
Non-Current Liabilities	$6.9M-14.7%	$8.1M-47.2%	$15.4M-25.5%	$20.7M+21.1%	$17.1M-80.7%	$88.4M-21.6%	$112.8M+9839.6%	$1.1M-99.2%	$146.4M+13019.6%	$1.1M+114.6%	$520K+612.3%	$73K+4.3%	$70K+900.0%	$7K-99.9%	$6.3M
Long-Term Debt	N/A	$0-100.0%	$6.3M-39.6%	$10.4M-31.2%	$15.1M	$0-100.0%	$168K-56.1%	$383K-36.1%	$599K	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.7M-65.1%	$19.1M-28.5%	$26.8M+47.8%	$18.1M-49.9%	$36.1M+152.5%	-$68.8M-36.6%	-$50.4M-171.0%	$71.0M+154.3%	-$130.7M-220.8%	$108.2M-14.7%	$126.8M+129.3%	$55.3M+32.7%	$41.7M+35.7%	$30.7M+1392.4%	-$2.4M
Retained Earnings	-$233.4M-12.7%	-$207.1M-25.3%	-$165.3M-21.7%	-$135.8M-35.7%	-$100.1M-39.4%	-$71.8M+65.6%	-$208.7M-27.2%	-$164.1M-19.9%	-$136.9M+45.3%	-$250.2M-49.0%	-$167.9M-77.3%	-$94.7M-109.6%	-$45.2M-180.0%	-$16.1M-514.9%	-$2.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$9.6M-60.7%	$10.7M-66.6%	$16.9M-59.2%	$17.1M-49.4%	$24.5M-41.9%	$32.2M-27.5%	$41.5M-19.6%	$33.8M+41.1%
Current Assets	$1.7M-88.8%	$2.4M-89.1%	$8.3M-73.7%	$8.1M-65.6%	$15.1M-52.1%	$22.4M-33.0%	$31.5M-22.0%	$23.6M+91.6%
Cash & Equivalents	$779K-94.5%	$1.8M-91.6%	$7.7M-74.5%	$7.5M-66.0%	$14.3M-54.1%	$21.5M-33.5%	$30.3M-22.8%	$22.1M+98.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$10.7M-27.1%	$9.9M-52.8%	$10.3M-54.1%	$10.8M-51.8%	$14.7M-41.7%	$21.0M-11.4%	$22.4M-10.0%	$22.4M-11.1%
Current Liabilities	$4.5M-37.7%	$3.3M-74.9%	$3.3M-76.7%	$3.5M-74.8%	$7.1M-51.0%	$13.2M+23.3%	$14.2M+51.1%	$14.0M+88.3%
Non-Current Liabilities	$6.3M-17.0%	$6.6M-15.8%	$6.9M-14.7%	$7.3M-13.7%	$7.6M-29.2%	$7.9M-39.8%	$8.1M-47.2%	$8.4M-52.7%
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$4.2M+1.4%	$0-100.0%	$0-100.0%
Total Equity	-$1.1M-111.1%	$822K-92.6%	$6.7M-65.1%	$6.3M-44.6%	$9.8M-42.2%	$11.1M-46.0%	$19.1M-28.5%	$11.5M+1062.8%
Retained Earnings	-$275.3M-21.9%	-$270.1M-23.9%	-$233.4M-12.7%	-$229.3M-18.7%	-$225.8M-23.6%	-$218.0M-25.9%	-$207.1M-25.3%	-$193.3M-22.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

TPST Cash Flow Statement

TPST quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$20.7M	-$26.8M+18.8%	-$33.0M-20.7%	-$27.4M+12.0%	-$31.1M-19.7%	-$26.0M-36.5%	-$19.0M+53.9%	-$41.2M-74.3%	-$23.6M-16.3%	-$20.3M+67.1%	-$61.7M-22.8%	-$50.3M-64.4%	-$30.6M-69.1%	-$18.1M-62.2%	-$11.2M	N/A
Depreciation & Amortization	N/A	$266K-31.6%	$389K+2.1%	$381K-40.3%	$638K+70.6%	$374K+10.3%	$339K+249.5%	$97K+203.1%	$32K-98.1%	$1.6M-26.3%	$2.2M+74.0%	$1.3M+185.8%	$450K+94.8%	$231K+148.4%	$93K	N/A
Stock-Based Compensation	N/A	$3.1M-41.2%	$5.3M+108.3%	$2.5M+63.1%	$1.6M+41.3%	$1.1M+143.9%	$453K-89.5%	$4.3M+202.5%	$1.4M-79.3%	$6.9M-25.2%	$9.2M-52.3%	$19.3M+55.9%	$12.4M+143.6%	$5.1M+268.6%	$1.4M	N/A
Capital Expenditures	$0	$0-100.0%	$435K+155.9%	$170K-69.8%	$562K+316.3%	$135K+170.0%	$50K-87.4%	$397K+1002.8%	$36K+800.0%	$4K-99.8%	$2.6M-50.5%	$5.2M+86.5%	$2.8M+290.0%	$719K-15.3%	$849K	N/A
Free Cash Flow	-$20.7M	-$26.8M+19.8%	-$33.5M-21.6%	-$27.5M+13.0%	-$31.6M-21.2%	-$26.1M-36.8%	-$19.1M+54.2%	-$41.6M-75.7%	-$23.7M-16.4%	-$20.3M+68.4%	-$64.3M-15.9%	-$55.5M-66.3%	-$33.4M-77.5%	-$18.8M-56.7%	-$12.0M	N/A
Investing Cash Flow	$0	$0+100.0%	-$435K-155.9%	-$170K+69.8%	-$562K-479.4%	-$97K-1516.7%	-$6K-100.2%	$4.0M+106.4%	$1.9M+321.8%	$458K-94.5%	$8.3M+121.7%	-$38.3M-16.8%	-$32.8M-197.6%	-$11.0M	N/A	N/A
Financing Cash Flow	$7.2M	$4.3M-82.6%	$24.5M-31.2%	$35.6M+212.2%	$11.4M-80.7%	$59.1M+70.7%	$34.6M+28.4%	$26.9M-65.3%	$77.7M+1842.0%	-$4.5M-108.2%	$54.1M-56.8%	$125.4M+142.5%	$51.7M+59.5%	$32.4M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.8M+67.0%	-$7.6M+5.5%	-$3.6M+64.8%	-$6.8M+33.4%	-$8.4M-53.0%	-$8.0M-11.8%	-$10.1M-64.4%	-$10.2M-57.0%
Depreciation & Amortization	$59K-11.9%	$60K-11.8%	$65K+32.7%	$66K-32.7%	$67K-56.8%	$68K-22.7%	$49K-42.4%	$98K+11.4%
Stock-Based Compensation	-$117K-110.7%	$226K-83.7%	N/A	$61K-95.4%	$1.1M-17.3%	$1.4M+5.4%	N/A	$1.3M+136.9%
Capital Expenditures	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$3K-57.1%	$15K
Free Cash Flow	-$2.8M+67.0%	-$7.6M+5.5%	-$3.6M+64.8%	-$6.8M+33.5%	-$8.4M-46.4%	-$8.0M-9.3%	-$10.2M-64.2%	-$10.2M-57.2%
Investing Cash Flow	$0	$0	$0+100.0%	$0+100.0%	$0+100.0%	$0+100.0%	-$3K+57.1%	-$15K
Financing Cash Flow	$1.8M+46.1%	$1.7M+335.2%	$3.8M-79.0%	$13K-99.2%	$1.2M-73.7%	-$721K-260.2%	$18.0M-47.7%	$1.5M+7238.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TPST Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TPST quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-167.8%	-727.1%	-711.9%	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-28585.1%	-12406.1%	-25992.4%	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-28670.5%	-12597.2%	-26432.9%	N/A	N/A	N/A	N/A
Return on Equity	-393.8%-175.1pp	-218.8%-108.6pp	-110.2%+87.0pp	-197.2%-118.8pp	-78.4%	N/A	N/A	-38.3%	N/A	-76.0%-18.3pp	-57.7%+31.8pp	-89.5%-19.9pp	-69.7%-25.7pp	-44.0%	N/A
Return on Assets	-155.1%-54.3pp	-100.9%-43.7pp	-57.1%+20.3pp	-77.5%-38.8pp	-38.6%+45.4pp	-84.0%-24.6pp	-59.5%-27.1pp	-32.3%+394.6pp	-426.9%-359.8pp	-67.1%-14.3pp	-52.8%+22.7pp	-75.5%-14.4pp	-61.1%-19.9pp	-41.2%	N/A
Current Ratio	2.50+0.3x	2.21-2.1x	4.29-0.2x	4.53+1.1x	3.44-2.7x	6.15+0.5x	5.68-2.8x	8.50+3.7x	4.82-4.0x	8.82-2.7x	11.55+5.5x	6.08-1.7x	7.81-7.5x	15.32+8.5x	6.79
Debt-to-Equity	1.54+1.5x	0.00-0.2x	0.23-0.3x	0.57+0.2x	0.42	N/A	N/A	0.01	N/A	0.130.0x	0.09-0.1x	0.190.0x	0.14+0.1x	0.07	N/A
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.010.0x	0.010.0x	0.000.0x	0.000.0x	0.00	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-6896.3%	-9849.9%	-20041.5%	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	N/A	-3369.3%-3271.8pp	N/A	-55.3%+36.8pp	-80.5%-24.0pp	-97.5%-59.2pp	N/A	-92.1%
Return on Assets	-54.4%-22.3pp	-257.7%-223.9pp	N/A	-20.5%+10.7pp	-32.1%-9.5pp	-33.8%-16.0pp	N/A	-31.2%-2.9pp
Current Ratio	0.38-1.7x	0.74-1.0x	2.50+0.3x	2.30+0.6x	2.12-0.1x	1.70-1.4x	2.21-2.1x	1.690.0x
Debt-to-Equity	N/A	12.08+11.7x	1.54+1.5x	1.70+1.7x	1.50+1.4x	0.38+0.2x	0.00-0.2x	0.00

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Tempest Therapeutics, Inc. TPST	FY2025	N/A	-$26.3M	N/A	$12.8M	—
Radiopharm Theranostics Limited RADX	FY2025	$3.6M	-$38.3M	N/A	$16.5M	20/100
Barinthus Biotherapeutics plc American BRNS	FY2025	$0	-$66.4M	N/A	$30.2M	—
Acrivon Therapeutics, Inc. ACRV	FY2025	N/A	-$77.9M	N/A	$81.8M	—
PLUS THERAPEUTICS, Inc. PSTV	FY2025	$5.2M	-$22.4M	N/A	$26.6M	32/100
Telomir Pharmaceuticals, Inc. TELO	FY2025	N/A	-$10.4M	N/A	$82.5M	—

Where Tempest Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Tempest Therapeutics, Inc. profitable?

No, Tempest Therapeutics, Inc. (TPST) reported a net income of -$26.3M in fiscal year 2025.

What is Tempest Therapeutics, Inc.'s EBITDA?

Tempest Therapeutics, Inc. (TPST) had EBITDA of -$26.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Tempest Therapeutics, Inc.'s return on equity (ROE)?

Tempest Therapeutics, Inc. (TPST) has a return on equity of -393.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Tempest Therapeutics, Inc.'s free cash flow?

Tempest Therapeutics, Inc. (TPST) recorded an outflow of $26.8M in free cash flow during fiscal year 2025. This represents a 19.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Tempest Therapeutics, Inc.'s operating cash flow?

Tempest Therapeutics, Inc. (TPST) recorded an outflow of $26.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Tempest Therapeutics, Inc.'s total assets?

Tempest Therapeutics, Inc. (TPST) had $16.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Tempest Therapeutics, Inc.'s capital expenditures?

Tempest Therapeutics, Inc. (TPST) reported no capital expenditure during fiscal year 2025.

How much does Tempest Therapeutics, Inc. spend on research and development?

Tempest Therapeutics, Inc. (TPST) invested $12.6M in research and development during fiscal year 2025.

How many shares does Tempest Therapeutics, Inc. have outstanding?

Tempest Therapeutics, Inc. (TPST) had 14M shares outstanding as of fiscal year 2025.

What is Tempest Therapeutics, Inc.'s current ratio?

Tempest Therapeutics, Inc. (TPST) had a current ratio of 2.50 as of fiscal year 2025, which is generally considered healthy.

What is Tempest Therapeutics, Inc.'s debt-to-equity ratio?

Tempest Therapeutics, Inc. (TPST) had a debt-to-equity ratio of 1.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tempest Therapeutics, Inc.'s return on assets (ROA)?

Tempest Therapeutics, Inc. (TPST) had a return on assets of -155.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Tempest Therapeutics, Inc.'s P/E ratio?

Tempest Therapeutics, Inc. (TPST) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $12.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Tempest Therapeutics, Inc.'s price-to-sales ratio?

Tempest Therapeutics, Inc. (TPST) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $12.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Tempest Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Tempest Therapeutics, Inc. (TPST) held $7.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $26.8M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Tempest Therapeutics, Inc.'s Piotroski F-Score?

Tempest Therapeutics, Inc. (TPST) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Tempest Therapeutics, Inc.'s earnings high quality?

Tempest Therapeutics, Inc. (TPST) reported a net loss of $26.3M while operations used $26.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Tempest Therapeutics, Inc. cover its interest payments?

Tempest Therapeutics, Inc. (TPST) reported an operating loss of $26.6M against $207K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.